144 related articles for article (PubMed ID: 37349947)
21. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
[TBL] [Abstract][Full Text] [Related]
22. Differential protein stability of EGFR mutants determines responsiveness to tyrosine kinase inhibitors.
Ray P; Tan YS; Somnay V; Mehta R; Sitto M; Ahsan A; Nyati S; Naughton JP; Bridges A; Zhao L; Rehemtulla A; Lawrence TS; Ray D; Nyati MK
Oncotarget; 2016 Oct; 7(42):68597-68613. PubMed ID: 27612423
[TBL] [Abstract][Full Text] [Related]
23. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
Assadollahi V; Rashidieh B; Alasvand M; Abdolahi A; Lopez JA
J Cell Biochem; 2019 Aug; 120(8):13046-13055. PubMed ID: 30916819
[TBL] [Abstract][Full Text] [Related]
24.
Imana SN; Ningsih EG; Tambunan USF
Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
[TBL] [Abstract][Full Text] [Related]
25. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
26. Identification of potent EGFR-TKD inhibitors from NPACT database through combined computational approaches.
Mir SA; Muhammad A; Padhiary A; Ekka NJ; Baitharu I; Naik PK; Nayak B
J Biomol Struct Dyn; 2023; 41(21):12063-12076. PubMed ID: 36695102
[TBL] [Abstract][Full Text] [Related]
27. Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR.
Todsaporn D; Mahalapbutr P; Poo-Arporn RP; Choowongkomon K; Rungrotmongkol T
Comput Biol Med; 2022 Aug; 147():105787. PubMed ID: 35803080
[TBL] [Abstract][Full Text] [Related]
28. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
[TBL] [Abstract][Full Text] [Related]
29. Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants.
García-Godoy MJ; López-Camacho E; García-Nieto J; Nebro AJ; Aldana-Montes JF
Molecules; 2016 Nov; 21(11):. PubMed ID: 27869781
[TBL] [Abstract][Full Text] [Related]
30. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
31. Atomic level and structural understanding of natural ligands inhibiting
Sunder Raj D; Kesavan DK; Kottaisamy CPD; Kumar VP; Hopper W; Sankaran U
J Biomol Struct Dyn; 2023 May; 41(8):3440-3461. PubMed ID: 35293845
[No Abstract] [Full Text] [Related]
32. Covalent vs. Non-Covalent Inhibition: Tackling Drug Resistance in EGFR - A Thorough Dynamic Perspective.
Akher FB; Farrokhzadeh A; Soliman MES
Chem Biodivers; 2019 Mar; 16(3):e1800518. PubMed ID: 30548188
[TBL] [Abstract][Full Text] [Related]
33. How Different Substitution Positions of F, Cl Atoms in Benzene Ring of 5-Methylpyrimidine Pyridine Derivatives Affect the Inhibition Ability of EGFR
E J; Liu Y; Guan S; Luo Z; Han F; Han W; Wang S; Zhang H
Molecules; 2020 Feb; 25(4):. PubMed ID: 32085409
[TBL] [Abstract][Full Text] [Related]
34. Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Wang DD; Ma L; Wong MP; Lee VH; Yan H
PLoS One; 2015; 10(5):e0128360. PubMed ID: 25993617
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Zhang X; Maity T; Kashyap MK; Bansal M; Venugopalan A; Singh S; Awasthi S; Marimuthu A; Charles Jacob HK; Belkina N; Pitts S; Cultraro CM; Gao S; Kirkali G; Biswas R; Chaerkady R; Califano A; Pandey A; Guha U
Mol Cell Proteomics; 2017 May; 16(5):891-910. PubMed ID: 28331001
[TBL] [Abstract][Full Text] [Related]
36. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting two cellular mutant epidermal growth factor receptor tyrosine kinases by addressing computationally assessed crystal ligand pockets.
Lee JH; Lin WC; Wen TK; Wang C; Lin YT
Future Med Chem; 2019 Apr; 11(8):833-846. PubMed ID: 30724109
[No Abstract] [Full Text] [Related]
38.
Patel HM; Ahmad I; Pawara R; Shaikh M; Surana S
J Biomol Struct Dyn; 2021 Mar; 39(4):1491-1505. PubMed ID: 32102624
[TBL] [Abstract][Full Text] [Related]
39. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
[TBL] [Abstract][Full Text] [Related]
40. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
Iqbal S; Anantha Krishnan D; Gunasekaran K
J Biomol Struct Dyn; 2018 Nov; 36(15):4029-4044. PubMed ID: 29182053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
